Natco's maraviroc request set to test India's intentions on compulsory licensing
This article was originally published in Scrip
Executive Summary
Natco Pharma's recent request to Pfizer seeking a voluntary licence to Pfizer's HIV entry inhibitor, maraviroc (Selzentry/Celsentri), is expected to serve as a test case on whether India is inclined to invoke compulsory licensing provisions to improve access to expensive drugs that are beyond the means of most of the country's HIV/AIDS patients.